(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -5.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Biontech Se's revenue in 2026 is $2,710,302,351.On average, 25 Wall Street analysts forecast BNTX's revenue for 2026 to be $464,369,481,140, with the lowest BNTX revenue forecast at $413,048,347,880, and the highest BNTX revenue forecast at $543,458,570,560. On average, 23 Wall Street analysts forecast BNTX's revenue for 2027 to be $455,939,923,020, with the lowest BNTX revenue forecast at $280,902,627,940, and the highest BNTX revenue forecast at $560,317,686,800.
In 2028, BNTX is forecast to generate $586,846,002,060 in revenue, with the lowest revenue forecast at $326,273,484,880 and the highest revenue forecast at $772,048,352,520.